GLP-1 agonists – of which Novo Nordisk’s Ozempic and Wegovy (semaglutide) and Eli Lilly’s Mounjaro (tirzepatide) are the most ...

Novo Nordisk A/S (NVO)'s share was trading at $109.09 as of Nov ... pricing dynamics linked to increased patient ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

Diabetes and weight-loss drug tirzepatide (Mounjaro, Zepbound) was listed as a contributing factor in the death of a 58-year-old nurse from Scotland who died of multiple organ failure, septic shock, ...

If you said diabetes, you're right -- a new study finds diabetes costs $101 billion annually in diagnosis and treatment and ...

Every earnings season has its share of outperformers, companies that report blowout quarters and raise their forecasts. The ...

Wegovy (semaglutide) is a GLP-1 receptor agonist that’s ... In a year-long study funded by Saxenda’s manufacturer, Novo Nordisk, people without diabetes who took Saxenda lost an average of 18 pounds.

A Scandinavian economic behemoth, Novo Nordisk is the highest valued company in Europe at over $500 billion, which exceeds ...

Ozempic, Mounjaro, Wegovy, Victoza and Trulicity are part of a class of ... consultation with a healthcare professional and ...

Lars Fruergaard Jørgensen began his career at Novo Nordisk as an economist in the health care, economy, and planning ...